In the News

Research advances from the National Institutes of Health (NIH) Intramural Research Program (IRP) often make headlines. Read the news releases that describe our most recent findings:

Featured Article

Here’s when your weight loss will plateau, according to science

CNN
Monday, April 22, 2024

Whether you’re shedding pounds with the help of effective new medicines, slimming down after weight loss surgery or cutting calories and adding exercise, there will come a day when the numbers on the scale stop going down, and you hit the dreaded weight loss plateau.

In a recent study, Kevin Hall, a researcher at the National Institutes of Health who specializes in measuring metabolism and weight change, looked at when weight loss typically stops depending on the method people were using to drop pounds. He broke down the plateau into mathematical models using data from high-quality clinical trials of different ways to lose weight to understand why people stop losing when they do. The study published Monday in the journal Obesity.

Two copies of mutant gene may trigger rare adrenal disorder

Mutation found by NIH, French team may allow for early identification of patients

Many cases of a rare disorder of the adrenal glands appear to result from two copies of a mutant gene, according to a research team made up of scientists in France and at the U.S. National Institutes of Health. The adrenal disorder, Corticotropin-independent macronodular adrenal hyperplasia External Web Site Policy, results in the formation of numerous tumors in the adrenal glands located on top of the kidneys, and which produce hormones that help the body respond to stress. The condition is one of many causes of Cushing’s syndrome, a group of symptoms resulting from an excess of cortisol, a stress hormone. Untreated, Cushing syndrome can result in high blood pressure, heart disease, bone loss, diabetes, and other health problems.

Gene-silencing study finds new targets for Parkinson’s disease

NIH study sheds light on treatment of related disorders

Scientists at the National Institutes of Health have used RNA interference (RNAi) technology to reveal dozens of genes which may represent new therapeutic targets for treating Parkinson’s disease. The findings also may be relevant to several diseases caused by damage to mitochondria, the biological power plants found in cells throughout the body.

NIH mouse study finds gut microorganisms may determine cancer treatment outcome

An intact population of microorganisms that derive food and benefit from other organisms living in the intestine is required for optimal response to cancer therapy, according to a mouse study by scientists at the National Cancer Institute (NCI), part of the National Institutes of Health, and their collaborators.

Researchers identify genomic variant associated with sun sensitivity, freckles

Researchers have identified a genomic variant strongly associated with sensitivity to the sun, brown hair, blue eyes – and freckles. In the study of Icelanders the researchers uncovered an intricate pathway involving the interspersed DNA sequence, or non-coding region, of a gene that is among a few dozen that are associated with human pigmentation traits.

NIH study finds low-intensity therapy for Burkitt lymphoma is highly effective

Adult patients with a type of cancer known as Burkitt lymphoma had excellent long-term survival rates — upwards of 90 percent — following treatment with low-intensity chemotherapy regimens, according to a new clinical trial finding. Standard treatment for Burkitt lymphoma involves high-dose chemotherapy, which has a high rate of toxicity, including death, and cures only 60 percent of adult patients. This trial was conducted by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, and appeared Nov. 14, 2013, in the New England Journal of Medicine.

NIH launches trial of investigational genital herpes vaccine

Researchers have launched an early-stage clinical trial of an investigational vaccine designed to prevent genital herpes disease. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring the Phase I trial, which is being conducted at the NIH Clinical Center in Bethesda, Md.

NIH scientists develop candidate vaccine against respiratory syncytial virus

Structure-based design may be key to successful vaccine for common childhood illness

An experimental vaccine to protect against respiratory syncytial virus (RSV), a leading cause of illness and hospitalization among very young children, elicited high levels of RSV-specific antibodies when tested in animals, according to a report in the journal Science.

Three NIH scientists elected to Institute of Medicine

Three scientists at the National Institutes of Health have been elected members of the Institute of Medicine. Election to the IOM is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.

Tanning gene linked to increased risk of testicular cancer, according to NIH scientists

A gene important in skin tanning has been linked to higher risk for testicular cancer in white men, according to a study led by scientists from the U.S. National Institutes of Health and the University of Oxford in England. Nearly 80 percent of white men carry a variant form of this gene, which increased risk of testicular cancer up to threefold in the study.

NIH researchers identify candidate drug to treat Batten disease

Mouse study suggests new drug could slow progress of fatal childhood disorder

Researchers at the National Institutes of Health have identified a potential new drug that could help in the treatment of a form of Batten disease, a fatal childhood disorder. The researchers tested the drug in mice with the disease and found that it slowed the loss of coordination seen in the disorder, and extended the animals’ life span.

Continue Exploring the IRP

This page was last updated on Monday, April 22, 2024